Explore

Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Lead Strategic Growth
Trendline Trendline
Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology

Roche Invests $1 Billion in C4 Therapeutics for Degrader-Antibody Conjugates in Oncology
Trendline Trendline
BostonGene Showcases AI-Driven Drug Development at AACR 2026

BostonGene Showcases AI-Driven Drug Development at AACR 2026

BostonGene Showcases AI-Driven Drug Development at AACR 2026
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment
Trendline Trendline
TAE Life Sciences Unveils Breakthrough in Boron Neutron Capture Therapy for Enhanced Tumor Control

TAE Life Sciences Unveils Breakthrough in Boron Neutron Capture Therapy for Enhanced Tumor Control

TAE Life Sciences Unveils Breakthrough in Boron Neutron Capture Therapy for Enhanced Tumor Control